iCAD

iCAD, Inc. is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iCAD implements strategic changes to drive profitability and growth

iCAD is strategically focusing on cost reduction, revenue diversification, and transitioning to a subscription model to drive profitability by 2024. Leveraging partnerships with Google and other organizations, the company aims to expand its market reach and enhance operational efficiency. Despite facing competition and market challenges, iCAD remains optimistic about its growth prospects.

iCAD reports Q1 revenue decline, eyes growth in AI healthcare

iCAD faced revenue decline in Q1 2023, with a focus on detection and therapy segments, while maintaining a strong gross profit margin.
The company's Xoft technology and partnership with Google Health present promising growth opportunities in the AI healthcare space.
Challenges include lower-than-expected Xoft business revenue, competition in AI software, and delays in partnership agreements.

iCAD reports Q2 revenue decline, eyes growth through strategic partnerships

iCAD's Q2 2023 Earnings Call showcased a revenue decline but highlighted progress in the detection segment and strategic partnerships. The company aims for recurring revenue through subscription deals and is focused on cost reductions and stability. Opportunities lie in expanding partnerships and securing growth with healthcare facilities globally.

iCAD reports improved operational metrics and strategic partnerships in Q3 '23

iCAD's Q3 '23 earnings call highlighted operational improvements, strategic partnerships, and a focus on growth initiatives. Despite a revenue decline and operating loss, the company has made progress in reducing EBITDA loss and cash burn. iCAD's financial position remains stable with sufficient resources for planned operations.

iCAD reports improved financials and strategic growth initiatives for 2024

iCAD's financial performance showed improvements in revenue, EBITDA loss, and operational efficiency, driven by strategic initiatives.
The company's focus on AI solutions, geographic expansion, and recurring revenue model positions it for future growth.
While facing challenges in market adoption and OpEx increases, iCAD has opportunities to capitalize on market growth and new product developments.

iCAD reports revenue growth and strategic expansion in Q1 2024

iCAD's Q1 2024 performance reflects positive momentum with revenue growth, improved profitability metrics, and strategic advancements
The company's focus on innovation, market expansion, and cost control positions them well for future growth and market leadership
While challenges like revenue seasonality and competitive pressures exist, iCAD's strengths in product development and global expansion offer opportunities for sustained growth
Overall, iCAD's Q1 2024 earnings call underscores a promising outlook with a strong foundation for continued success in the medical technology sector

iCAD reports 4% revenue growth, FDA clearance boosts cancer detection

iCAD's Q3 performance reflects growth in revenue and strategic partnerships, underpinned by AI technology.
While facing challenges in service revenue and net loss, the company's global expansion and product advancements signal resilience.
Opportunities lie in market expansion, innovation in breast cancer detection, and transitioning to a recurring revenue model.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

NASHUA, N.H., Jan. 19, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Michael Klein, iCAD's Chairman and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20 at 11:00am ET and will also conduct one-on-one meetings with investors.

iCAD to Participate in B. Riley Securities Virtual Oncology Investor Conference

New ProFound AI risk software, offering a 2-year projected risk score to be featured New ProFound AI risk software, offering a 2-year projected risk score to be featured

iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

International Multi-Center Study to Commence January 2021

iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption

Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services' Network Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services' Network

Solis Mammography Adopts iCAD's ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution

Groundbreaking ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm to Risk-Adapted Precision Screening, Individualized for Each Woman Groundbreaking ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm to Risk-Adapted Precision Screening, Individualized for Each Woman

iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020

Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types

iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress

Significant Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with Multiple Vendors Including Hologic and Fuji

iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales

iCAD, Inc. (ICAD) CEO Michael Klein on Q3 2020 Results - Earnings Call Transcript

Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth of 44% and 251%, Respectively

iCAD Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020

NASHUA, N.H., Oct. 29, 2020 (GLOBE NEWSWIRE) --  iCAD , Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2020, after the market close, and host a conference call at 4:30pm Eastern Time on Thursday, November 5.

iCAD to Report Third Quarter 2020 Financial Results on Thursday, November 5

iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors

New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers

Contract with market-leading enterprise imaging provider expands access to ProFound AI for hospitals and imaging centers across North America Contract with market-leading enterprise imaging provider expands access to ProFound AI for hospitals and imaging centers across North America

iCAD Signs Distribution Agreement with Change Healthcare

New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery 

New Data Supports iCAD's Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma

Webinar Taking Place on Wednesday, October 21st @ 10amET Webinar Taking Place on Wednesday, October 21st @ 10amET

iCAD Hosting Technology Innovation Webinar on the Evolving Landscape for Treating Patients with Brain, Breast, and Rectal Cancers

IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced

iCAD Responds to CMS’ Finalized Radiation Oncology Alternative Payment Model

NASHUA, N.H., Sept.  18, 2020  (GLOBE NEWSWIRE) --  iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today provided commentary on the Center for Medicare and Medicaid Services’ (CMS) Radiation Oncology alternative payment model (RO-APM), which was published today. The new model does not include coverage for iCAD’s intraoperative radiation therapy (IORT) as part of the new bundled payment system. iCAD’s IORT will still be covered under its existing CMS reimbursement codes in all geographic markets.

iCAD’s IORT Excluded from CMS’s Radiation Oncology Alternative Payment Model

Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settings Leading experts in multiple disciplines to share best practices on leveraging AI in clinical settings

iCAD Hosts Free Virtual Roundtable Event Focusing on Making Informed Decisions for Adopting New AI Solutions and Practical Applications in Healthcare

NASHUA, N.H., Aug.  27, 2020  (GLOBE NEWSWIRE) --  iCAD, Inc.  (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that management will present at the LD 500 Virtual Conference, hosted by LD Micro and taking place virtually September 1 – 4, 2020.

iCAD to Present at the LD Micro 500 Virtual Conference

iCAD, Inc. (ICAD) CEO Michael Klein on Q2 2020 Results - Earnings Call Transcript

Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe

iCAD Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020

NASHUA, N.H., July  28, 2020  (GLOBE NEWSWIRE) --  iCAD, Inc.  (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter and six-months ended June 30, 2020, after the market close, and host a conference call at 4:30 pm Eastern Time on Tuesday, August 4.

iCAD to Report Second Quarter 2020 Financial Results on Tuesday, August 4

First and only commercially available clinical decision support tool provides accurate    two-year breast cancer risk estimation personalized for each woman

ProFound AI™ Risk Receives CE Mark in Europe

Leading-edge artificial intelligence (AI) software allows patients to receive “real time” essential breast screening amidst pandemic Leading-edge artificial intelligence (AI) software allows patients to receive “real time” essential breast screening amidst pandemic

SimonMed Imaging Accelerates Nationwide Deployment of iCAD’s ProFound AI™

NASHUA, N.H., June  29, 2020  (GLOBE NEWSWIRE) --  iCAD , Inc . (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the company has been added to the Russell 2000® Index and the Russell 3000® Index at the conclusion of this year’s reconstitution of the Russell stock indexes, effective upon the opening of the U.S. stock markets today, Monday, June 29, 2020.

iCAD Added to Russell 2000® Index

NASHUA, N.H., April  23, 2020  (GLOBE NEWSWIRE) -- iCAD, Inc. (“iCAD”) (Nasdaq: ICAD) today announced it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,562,500  shares of the Company’s common stock  at $8.00 per share, pursuant to a registered direct offering. The gross proceeds of the offering will be approximately $12.5 million before deducting estimated offering expenses. The Company intends to use the net proceeds for working capital and for other general corporate purposes, including for the conduct of post-market studies for the Company’s Xoft intra-operative radiation therapy (IORT) for glioblastoma and other brain cancers. The closing of the registered direct offering is expected to take place on or about April 27, 2020, subject to the satisfaction of customary closing conditions.  

News for iCAD Stock (ICAD)